

# Ruud P M Dings

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1286241/publications.pdf>

Version: 2024-02-01

72  
papers

4,209  
citations

117453

34  
h-index

110170

64  
g-index

75  
all docs

75  
docs citations

75  
times ranked

5950  
citing authors

#	ARTICLE	IF	CITATIONS
1	Spectroscopic investigation of radiation-induced reoxygenation in radiation-resistant tumors. <i>Neoplasia</i> , 2021, 23, 49-57.	2.3	7
2	Dendritic cell biocompatibility of ether-based urethane films. <i>Journal of Applied Toxicology</i> , 2021, 41, 1456-1466.	1.4	2
3	Dysbiotic stress increases the sensitivity of the tumor vasculature to radiotherapy and c-Met inhibitors. <i>Angiogenesis</i> , 2021, 24, 597-611.	3.7	3
4	Nanoscale investigation and control of photothermal action of gold nanostructure-coated surfaces. <i>Journal of Materials Science</i> , 2021, 56, 10249-10263.	1.7	3
5	Gold nanorods enhance different immune cells and allow for efficient targeting of CD4+ Foxp3+ Tregulatory cells. <i>PLoS ONE</i> , 2021, 16, e0241882.	1.1	3
6	Simulating cellular galectin networks by mixing galectins in vitro reveals synergistic activity. <i>Biochemistry and Biophysics Reports</i> , 2021, 28, 101116.	0.7	2
7	Evidence for Early Stage Anti-Tumor Immunity Elicited by Spatially Fractionated Radiotherapy-Immunotherapy Combinations. <i>Radiation Research</i> , 2020, 194, 688-697.	0.7	29
8	Gastrointestinal Tract Dysbiosis Enhances Distal Tumor Progression through Suppression of Leukocyte Trafficking. <i>Cancer Research</i> , 2019, 79, 5999-6009.	0.4	21
9	Enhanced Photothermal Treatment Efficacy and Normal Tissue Protection via Vascular Targeted Gold Nanocages. <i>Nanotheranostics</i> , 2019, 3, 145-155.	2.7	10
10	Label-Free Raman Spectroscopy Reveals Signatures of Radiation Resistance in the Tumor Microenvironment. <i>Cancer Research</i> , 2019, 79, 2054-2064.	0.4	53
11	Glutaminase inhibitor CB-839 increases radiation sensitivity of lung tumor cells and human lung tumor xenografts in mice. <i>International Journal of Radiation Biology</i> , 2019, 95, 436-442.	1.0	77
12	Galectin-1-based tumour-targeting for gold nanostructure-mediated photothermal therapy. <i>International Journal of Hyperthermia</i> , 2018, 34, 19-29.	1.1	16
13	Rapid quantification of mitochondrial fractal dimension in individual cells. <i>Biomedical Optics Express</i> , 2018, 9, 5269.	1.5	9
14	Sample storage conditions induce post-collection biases in microbiome profiles. <i>BMC Microbiology</i> , 2018, 18, 227.	1.3	23
15	Consensus guidelines for the use and interpretation of angiogenesis assays. <i>Angiogenesis</i> , 2018, 21, 425-532.	3.7	429
16	Galectins as Molecular Targets for Therapeutic Intervention. <i>International Journal of Molecular Sciences</i> , 2018, 19, 905.	1.8	83
17	Design of Gold Nanoparticles in Dendritic Cell-Based Vaccines. <i>Particle and Particle Systems Characterization</i> , 2018, 35, 1800109.	1.2	13
18	Hypoxia-derived exosomes induce putative altered pathways in biosynthesis and ion regulatory channels in glioblastoma cells. <i>Biochemistry and Biophysics Reports</i> , 2018, 14, 104-113.	0.7	65

#	ARTICLE	IF	CITATIONS
19	A Radiosensitizing Inhibitor of HIF-1 alters the Optical Redox State of Human Lung Cancer Cells In Vitro. <i>Scientific Reports</i> , 2018, 8, 8815.	1.6	18
20	Quantitative diffuse reflectance spectroscopy of short-term changes in tumor oxygenation after radiation in a matched model of radiation resistance. <i>Biomedical Optics Express</i> , 2018, 9, 3794.	1.5	15
21	Real-time monitoring of circulating tumor cell (CTC) release after nanodrug or tumor radiotherapy using inÂvivo flow cytometry. <i>Biochemical and Biophysical Research Communications</i> , 2017, 492, 507-512.	1.0	18
22	Triple-negative breast cancer targeting and killing by EpCAM-directed, plasmonically active nanodrug systems. <i>Npj Precision Oncology</i> , 2017, 1, 27.	2.3	34
23	Modifying Dendritic Cell Activation with Plasmonic Nano Vectors. <i>Scientific Reports</i> , 2017, 7, 5513.	1.6	25
24	Optical imaging and spectroscopy of microenvironmental changes associated with radiation resistance in tumors. <i>Proceedings of SPIE</i> , 2017, , .	0.8	0
25	Optical imaging of radiation-induced metabolic changes in radiation-sensitive and resistant cancer cells. <i>Journal of Biomedical Optics</i> , 2017, 22, 060502.	1.4	19
26	Galectin-1 Inhibitor OTX008 Induces Tumor Vessel Normalization and Tumor Growth Inhibition in Human Head and Neck Squamous Cell Carcinoma Models. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2671.	1.8	37
27	Quantitative Diffuse Optical Spectroscopy of Short-term Reoxygenation Kinetics in Radiation-Resistant and Sensitive Tumors. , 2017, , .		0
28	Determining the Sensitivity of Diffuse Reflectance Spectroscopy to Dose- and Depth-Dependent Changes in Tumor Oxygenation after Radiation Therapy. , 2017, , .		1
29	Further rationale for optimal combined modality treatments. <i>Oncotarget</i> , 2017, 8, 25831-25832.	0.8	0
30	Targeting Artificial Tumor Stromal Targets for Molecular Imaging of Tumor Vascular Hypoxia. <i>PLoS ONE</i> , 2015, 10, e0135607.	1.1	15
31	Combination of Gold Nanoparticle-Conjugated Tumor Necrosis Factor-Î± and Radiation Therapy Results in a Synergistic Antitumor Response in Murine Carcinoma Models. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 588-596.	0.4	52
32	Novel analogs of antitumor agent calixarene O118: Synthesis, cytotoxicity, click labeling with 2-[18F]fluoroethylazide, and inÂvivo evaluation. <i>European Journal of Medicinal Chemistry</i> , 2015, 89, 279-295.	2.6	38
33	Polycationic calixarene PTX013, a potent cytotoxic agent against tumors and drug resistant cancer. <i>Investigational New Drugs</i> , 2013, 31, 1142-1150.	1.2	44
34	Bacterial membrane disrupting dodecapeptide SC4 improves survival of mice challenged with <i>Pseudomonas aeruginosa</i> . <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2013, 1830, 3454-3457.	1.1	8
35	Structure-Based Optimization of Angiostatic Agent 6DBF7, an Allosteric Antagonist of Galectin-1. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2013, 344, 589-599.	1.3	36
36	Informa-Yamamoto Editorial Award Winners 2011. <i>International Journal of Hyperthermia</i> , 2012, 28, 419-420.	1.1	0

#	ARTICLE	IF	CITATIONS
37	Antitumor Agent Calixarene 0118 Targets Human Galectin-1 as an Allosteric Inhibitor of Carbohydrate Binding. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 5121-5129.	2.9	113
38	Microbeam Radiation Therapy Alters Vascular Architecture and Tumor Oxygenation and is Enhanced by a Galectin-1 Targeted Anti-Angiogenic Peptide. <i>Radiation Research</i> , 2012, 177, 804-812.	0.7	54
39	Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells. <i>Scientific Reports</i> , 2012, 2, 362.	1.6	233
40	Synthesis of [ <sup>18</sup> F]anginex with high specific activity [ <sup>18</sup> F]fluorobenzaldehyde for targeting angiogenic activity in solid tumors. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2011, 54, 708-713.	0.5	3
41	Enhancement of T-cell-Mediated Antitumor Response: Angiostatic Adjuvant to Immunotherapy against Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 3134-3145.	3.2	64
42	Tumour thermotolerance, a physiological phenomenon involving vessel normalisation. <i>International Journal of Hyperthermia</i> , 2011, 27, 42-52.	1.1	24
43	Inhibiting Tumor Growth by Targeting Tumor Vasculature with Galectin-1 Antagonist Anginex Conjugated to the Cytotoxic Acylfulvene, 6-Hydroxylpropylacylfulvene. <i>Bioconjugate Chemistry</i> , 2010, 21, 20-27.	1.8	40
44	Mild temperature hyperthermia and radiation therapy: Role of tumour vascular thermotolerance and relevant physiological factors. <i>International Journal of Hyperthermia</i> , 2010, 26, 256-263.	1.1	65
45	Dietary lariciresinol attenuates mammary tumor growth and reduces blood vessel density in human MCF7 breast cancer xenografts and carcinogen-induced mammary tumors in rats. <i>International Journal of Cancer</i> , 2008, 123, 1196-1204.	2.3	42
46	Ovarian tumor growth regression using a combination of vascular targeting agents anginex or topomimetic 0118 and the chemotherapeutic irifolven. <i>Cancer Letters</i> , 2008, 265, 270-280.	3.2	48
47	Probing structure-activity relationships in bactericidal peptide Î²-pep-25. <i>Biochemical Journal</i> , 2008, 414, 143-150.	1.7	8
48	Non-Peptidic Mimetics as Cancer-Sensitizing Agents. , 2008, , 305-325.		1
49	Scheduling of Radiation with Angiogenesis Inhibitors Anginex and Avastin Improves Therapeutic Outcome via Vessel Normalization. <i>Clinical Cancer Research</i> , 2007, 13, 3395-3402.	3.2	270
50	Modulation of Angiogenic Phenotype Alters Tumorigenicity in Rat Ovarian Epithelial Cells. <i>Cancer Research</i> , 2007, 67, 3683-3690.	0.4	36
51	A Journey in Structure-Based Drug Discovery: From Designed Peptides to Protein Surface Topomimetics as Antibiotic and Antiangiogenic Agents. <i>Accounts of Chemical Research</i> , 2007, 40, 1057-1065.	7.6	39
52	Antiangiogenesis therapy using a novel angiogenesis inhibitor, anginex, following radiation causes tumor growth delay. <i>International Journal of Clinical Oncology</i> , 2007, 12, 42-47.	1.0	33
53	Topomimetics of Amphipathic Î²-Sheet and Helix-Forming Bactericidal Peptides Neutralize Lipopolysaccharide Endotoxins. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 7754-7765.	2.9	56
54	Design of Nonpeptidic Topomimetics of Antiangiogenic Proteins With Antitumor Activities. <i>Journal of the National Cancer Institute</i> , 2006, 98, 932-936.	3.0	102

#	ARTICLE	IF	CITATIONS
55	Anti-angiogenesis and anti-tumor activity of recombinant anginex. <i>Biochemical and Biophysical Research Communications</i> , 2006, 349, 1073-1078.	1.0	28
56	Gene expression of tumor angiogenesis dissected: specific targeting of colon cancer angiogenic vasculature. <i>Blood</i> , 2006, 108, 2339-2348.	0.6	226
57	Epigenetic Regulation of Tumor Endothelial Cell Anergy: Silencing of Intercellular Adhesion Molecule-1 by Histone Modifications. <i>Cancer Research</i> , 2006, 66, 10770-10777.	0.4	139
58	Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 15975-15980.	3.3	424
59	Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors. <i>FASEB Journal</i> , 2006, 20, 621-630.	0.2	237
60	Anginex synergizes with radiation therapy to inhibit tumor growth by radiosensitizing endothelial cells. <i>International Journal of Cancer</i> , 2005, 115, 312-319.	2.3	81
61	Cloning an artificial gene encoding angiostatic anginex: From designed peptide to functional recombinant protein. <i>Biochemical and Biophysical Research Communications</i> , 2005, 333, 1261-1268.	1.0	25
62	VEGF <sup>DT385</sup> Toxin Conjugate Inhibits Mammary Adenocarcinoma Development in a Transgenic Mouse Model of Spontaneous Tumorigenesis. <i>Breast Cancer Research and Treatment</i> , 2004, 85, 161-171.	1.1	11
63	Carboplatin selectively induces the VEGF stress response in endothelial cells: Potentiation of antitumor activity by combination treatment with antibody to VEGF. <i>International Journal of Cancer</i> , 2004, 110, 343-351.	2.3	53
64	Angiogenesis gene expression profiling in xenograft models to study cellular interactions. <i>Experimental Cell Research</i> , 2004, 299, 286-293.	1.2	76
65	Discovery and development of anti-angiogenic peptides: A structural link. <i>Angiogenesis</i> , 2003, 6, 83-91.	3.7	23
66	Anti-tumor activity of the novel angiogenesis inhibitor anginex. <i>Cancer Letters</i> , 2003, 194, 55-66.	3.2	65
67	Design of a Partial Peptide Mimetic of Anginex with Antiangiogenic and Anticancer Activity. <i>Journal of Biological Chemistry</i> , 2003, 278, 45746-45752.	1.6	62
68	beta-Sheet is the bioactive conformation of the anti-angiogenic anginex peptide. <i>Biochemical Journal</i> , 2003, 373, 281-288.	1.7	51
69	The designed angiostatic peptide anginex synergistically improves chemotherapy and antiangiogenesis therapy with angiostatin. <i>Cancer Research</i> , 2003, 63, 382-5.	0.4	85
70	The designer antiangiogenic peptide anginex targets tumor endothelial cells and inhibits tumor growth in animal models. <i>FASEB Journal</i> , 2002, 16, 1991-1993.	0.2	96
71	Tumor angiogenesis factors reduce leukocyte adhesion in vivo. <i>International Immunology</i> , 2000, 12, 671-676.	1.8	61
72	Understanding Galectin Structure-Function Relationships to Design Effective Antagonists. , 0, , 33-69.		15